Patient disposition and baseline characteristics
PANCREATIC ADENOCARCINOMA, APPENDIX
Of 162 molecularly eligible patients, 96 patients received a MoST MTB recommendation indicating trial eligibility. Forty-eight patients were subsequently enrolled on trial over a 15-month period (November 2017 and February 2019) and allocated to the two study cohorts (groups 1 and 2). Reasons for non-enrolment on trial are outlined in Appendix Pancreatic adenocarcinomas (